Irina Mezhebovsky
Brookline, MANPI 1114981073
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$3,839,330in research payments, 2019–2025
Across 289 payments — averaging $13,285 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2.4M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$430K
- Janssen Research & Development, LLC$206K
- Boehringer Ingelheim$197K
- F. Hoffmann-la Roche AG$133K
- Supernus Pharmaceuticals, Inc.$109K
- plus $382K from 9 others
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.